Download PDF
1 / Pages

Other users also viewed these articles

Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel A. Araújo; A. Barroso; B. Parente; C. Travancinha; E. Teixeira; F. Martelo; G. Fernandes; G. Paupério; H. Queiroga; I. Duarte; J.D. da Costa; M. Soares; P. Borralho; P. Costa; P. Chinita; T. Almodôvar; F. Barata;
Pulmonol. 2024;30:159-69
Never Give Up: Lesson learned from a severe COVID-19 patient R. Tonelli; A. Iattoni; M. Girardis; L. De Pietri; E. Clini; C. Mussini;
Pulmonol. 2021;27:257-60
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study F. Barata; H. Queiroga; E. Teixeira; T. Almodovar; M. Soares; B. Parente; J.C. Mellidez; P. Alves; A. Antunes;
Pulmonol. 2021;27:175-7